메디톡스, 연간 퇴사율 23%…인력 이탈 경고등

High employee turnover and executive departures at Medytox pose a critical threat to its global expansion and the complex FDA approval process for MT10109L. The loss of institutional knowledge in R&D and strategic planning units signals a deepening organizational risk that could delay regulatory recovery and weaken its position against domestic competitors.